Jeito Capital Becomes Key Investor in NMD Pharma as Part of a €35 Million New Financing | Business Wire
NMD Pharma
NMD Pharma A/S | LinkedIn
NMD Pharma is about to start a combined Phase I/IIa clinical trial with its ClC-1 channel inhibitor in healthy subjects and patients with myasthenia gravis – ION CHANNEL LIBRARY
NMD Pharma company information, funding & investors | Dealroom.co